Johann-Martin Hempel1, Jens Schittenhelm2, Uwe Klose3, Benjamin Bender3, Georg Bier3, Marco Skardelly4, Ghazaleh Tabatabai5, Salvador Castaneda Vega6, Ulrike Ernemann3, Cornelia Brendle3. 1. Department of Neuroradiology, Eberhard Karls University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany. johann-martin.hempel@uni-tuebingen.de. 2. Institute of Neuropathology, Eberhard Karls University, Tübingen, Germany. 3. Department of Neuroradiology, Eberhard Karls University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany. 4. Department of Neurosurgery, Eberhard Karls University, Tübingen, Germany. 5. Centre of Neurooncology, Comprehensive Cancer Center Tübingen-Stuttgart, Eberhard Karls University, Tübingen, Germany. 6. Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany.
Abstract
PURPOSE: To assess the diagnostic performance of dynamic susceptibility contrast perfusion magnetic resonance perfusion imaging (DSC-MRI) for in vivo human glioma molecular profiling. METHODS: In this study 100 patients with histopathologically confirmed glioma who provided written informed consent were retrospectively assessed between January 2016 and February 2017 in two prospective trials that were approved by the local institutional review board. Cerebral blood volume (CBV) measurements from DSC-MRI were assessed, and histogram parameters of relative CBV (rCBV) results were compared among World Health Organization (WHO) 2016 based histological findings and molecular characteristics. A classification and regression tree (CART) algorithm with 10-fold cross-validation was used to calculate the diagnostic accuracy. RESULTS: The 90th percentile (C90) of rCBV was significantly lower in patients with the isocitrate dehydrogenase 1/2 (IDH1/2) mutation (2.86 ± 1.21; p < 0.001) and loss of alpha-thalassemia mental retardation syndrome X‑linked (ATRX) expression (2.23 ± 0.91; p < 0.001) than in those with the IDH1/2 wild type (4.78 ± 2.34) and maintained ATRX expression (4.30 ± 2.02). The standard deviation (SD) of rCBV was significantly higher in glioblastoma (GBM) with methylated O6-methylguanine DNA methyltransferase (MGMT; 1.99 ± 0.73; p = 0.001) than in those with unmethylated MGMT (1.20 ± 0.45). In CART analysis, rCBV predicted the molecular subgroup in 76.3% of astroglial tumors; however, the diagnostic performance was reduced to 48.1% by including oligodendrogliomas with chromosome 1p/19q co-deletion in the analysis due to substantial overlap of rCBV values between OD1p/19q-LOH and IDHwt GBM. CONCLUSION: The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
PURPOSE: To assess the diagnostic performance of dynamic susceptibility contrast perfusion magnetic resonance perfusion imaging (DSC-MRI) for in vivo human glioma molecular profiling. METHODS: In this study 100 patients with histopathologically confirmed glioma who provided written informed consent were retrospectively assessed between January 2016 and February 2017 in two prospective trials that were approved by the local institutional review board. Cerebral blood volume (CBV) measurements from DSC-MRI were assessed, and histogram parameters of relative CBV (rCBV) results were compared among World Health Organization (WHO) 2016 based histological findings and molecular characteristics. A classification and regression tree (CART) algorithm with 10-fold cross-validation was used to calculate the diagnostic accuracy. RESULTS: The 90th percentile (C90) of rCBV was significantly lower in patients with the isocitrate dehydrogenase 1/2 (IDH1/2) mutation (2.86 ± 1.21; p < 0.001) and loss of alpha-thalassemia mental retardation syndrome X‑linked (ATRX) expression (2.23 ± 0.91; p < 0.001) than in those with the IDH1/2 wild type (4.78 ± 2.34) and maintained ATRX expression (4.30 ± 2.02). The standard deviation (SD) of rCBV was significantly higher in glioblastoma (GBM) with methylated O6-methylguanine DNA methyltransferase (MGMT; 1.99 ± 0.73; p = 0.001) than in those with unmethylated MGMT (1.20 ± 0.45). In CART analysis, rCBV predicted the molecular subgroup in 76.3% of astroglial tumors; however, the diagnostic performance was reduced to 48.1% by including oligodendrogliomas with chromosome 1p/19q co-deletion in the analysis due to substantial overlap of rCBV values between OD1p/19q-LOH and IDHwt GBM. CONCLUSION: The DSC-MRI procedure may provide insight into the IDH1/2 mutation and ATRX expression status and MGMT methylation profile of diffuse glioma; however, taking integrated oligodendroglioma into account limits the diagnostic performance of rCBV in non-invasively predicting the molecular subtype.
Authors: Soonmee Cha; Tarik Tihan; Forrest Crawford; Nancy J Fischbein; Susan Chang; Andrew Bollen; Sarah J Nelson; Michael Prados; Mitchel S Berger; William P Dillon Journal: AJNR Am J Neuroradiol Date: 2005-02 Impact factor: 3.825
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: Robert G Whitmore; Jaroslaw Krejza; Gurpreet S Kapoor; Jason Huse; John H Woo; Stephanie Bloom; Joanna Lopinto; Ronald L Wolf; Kevin Judy; Myrna R Rosenfeld; Jaclyn A Biegel; Elias R Melhem; Donald M O'Rourke Journal: J Neurosurg Date: 2007-09 Impact factor: 5.115
Authors: S J Price; R Jena; N G Burnet; P J Hutchinson; A F Dean; A Peña; J D Pickard; T A Carpenter; J H Gillard Journal: AJNR Am J Neuroradiol Date: 2006-10 Impact factor: 3.825
Authors: Daniel J Tozer; H Rolf Jäger; Nasuda Danchaivijitr; Christopher E Benton; Paul S Tofts; Jeremy H Rees; Adam D Waldman Journal: NMR Biomed Date: 2007-02 Impact factor: 4.044
Authors: Paulina Due-Tønnessen; Marco C Pinho; Kyrre E Emblem; John K Hald; Masafumi Kanoto; Andreas Abildgaard; Donatas Sederevicius; Inge R Groote; Otto Rapalino; Atle Bjørnerud Journal: Sci Rep Date: 2019-12-27 Impact factor: 4.379
Authors: Elies Fuster-Garcia; David Lorente Estellés; María Del Mar Álvarez-Torres; Javier Juan-Albarracín; Eduard Chelebian; Alex Rovira; Cristina Auger Acosta; Jose Pineda; Laura Oleaga; Enrique Mollá-Olmos; Silvano Filice; Paulina Due-Tønnessen; Torstein R Meling; Kyrre E Emblem; Juan M García-Gómez Journal: Eur Radiol Date: 2020-10-01 Impact factor: 5.315